

Correspondence

Edited by Kiriakos Xenitidis and
Colin Campbell

Contents

- Dose and effect in CBT for schizophrenia
- Should adherence to antidepressants be judged in isolation in ischaemic heart disease?
- Are NICE guidelines losing their impartiality?
- Hearing voices: are we getting the message?
- Childhood non-affective psychoses: data analysis

Dose and effect in CBT for schizophrenia

Many thanks to Jauhar and colleagues for their interesting and thought-provoking review of cognitive-behavioural therapy (CBT) for schizophrenia,¹ and especially for making their data publicly available. Previous discussants (Byrne,² McKenna *et al*)³ have commented on the lack of consideration given to ‘dose’ (i.e. number of sessions) of CBT. The relation between dose and effect is almost a classic in psychotherapy research.⁴ It has more recently been shown to be of importance in reviews of other psychosocial therapies (e.g. Gold *et al*).⁵ Together with the obvious plausibility of such a relationship, this seems to be enough reason to examine the dose–effect relation carefully. I used the effect sizes calculated by Jauhar *et al* and extracted the number of sessions from the original papers (I was able to do this for 32 of the 52 studies). I then ran a meta-regression (functions *metagen* and *metareg* from R package *meta*) for each of the four outcomes (Fig. 1). Most studies used between 10 and 20 sessions, with a few outliers in both directions. The regression lines show little support for an increase of effect with dose. On the contrary, there are tendencies in the opposite direction for all outcomes. The paradoxical observation is that effects seem to be strongest when

few sessions were provided (significant for positive symptoms, $P = 0.0005$).

Obviously this analysis has a number of limitations.

- (a) As McKenna *et al*³ noted in their response to the comment by Byrne,² participants were not randomised to different doses.
- (b) Dose is likely confounded with duration⁶ and may also be confounded with masking and control interventions.¹
- (c) There may be differences between the scheduled and the received dose, and this was not reported consistently in the original papers.
- (d) Dose data were not independently extracted by two people.

However, I think one can conclude from these analyses that dose is unlikely to have masked a clearer effect in these data. A more detailed re-analysis of this data-set may be warranted. In general, the dosage of psychotherapy should be considered carefully in future studies.

- 1 Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *Br J Psychiatry* 2014; **204**: 20–9.
- 2 Byrne RE. CBT for psychosis: not a ‘quasi-neuroleptic’. *Br J Psychiatry* 2014; **204**: 489.
- 3 McKenna PJ, Radua J, Jauhar S, Laws KR. Authors’ reply. *Br J Psychiatry* 2014; **204**: 490.
- 4 Howard KI, Kopta SM, Krause MS, Orlinsky DE. The dose-effect relationship in psychotherapy. *Am Psychol* 1986; **41**: 159–64.
- 5 Gold C, Solli HP, Krüger V, Lie SA. Dose-response relationship in music therapy for people with serious mental disorders: systematic review and meta-analysis. *Clin Psychol Rev* 2009; **29**: 193–207.
- 6 Gold C. Quantitative psychotherapy outcome research: methodological issues. In *Psychotherapy Research: Foundations, Process, and Outcome* (eds OCG Gelo, A Pritz, B Rieken): 537–58. Springer, 2015.

Christian Gold, Principal Researcher, Professor, Uni Research Health, Bergen, Norway. Email: christian.gold@uni.no

doi: 10.1192/bjp.207.3.269

Authors’ reply: Gold’s findings using the end-of-treatment effect sizes from our meta-analysis of CBT for schizophrenia¹




Fig. 1 Meta-regression for (a) total symptoms, (b) positive symptoms, (c) negative symptoms and (d) hallucinations.